6 December 2019 in Science Advances
A single ATPase powers extension and retraction of a broadly distributed class of type IV pili.
20 February 2024 in mSystems
The emergence of biochemically and genetically tractable host model organisms for infection studies holds the promise to accelerate the pace of discoveries related to the evolution of innate immunity and the dissection of conserved mechanisms of cell-autonomous defenses. Here, we have used the genetically and biochemically tractable infection model system Dictyostelium discoideum / Mycobacterium marinum to apply a genome-wide transposon-sequencing experimental strategy to reveal comprehensively which mutations confer a fitness advantage or disadvantage during infection and compare these to a similar experiment performed using the murine microglial BV2 cells as host for M. marinum to identify conservation of virulence pathways between hosts.
2 December 2025 in Microbiology Spectrum
The rising prevalence of multidrug-resistant Klebsiella
pneumoniae strains, particularly the emerging high-risk ST16 lineage, highlights the urgent need for alternative therapeutic strategies. A major barrier to effective bacteriophage (phage) therapy against K. pneumoniae is its polysaccharide capsule, which hinders phage access to surface receptors. In this study, we identified and characterized an anti-KL51 capsule depolymerase derived from the anti-ST16 phage PWKp9B. The recombinant DpoK51-9B enzyme was expressed in Escherichia coli , purified, and shown to degrade the KL51 capsule using Percoll density gradient, halo formation on double-layered-agar, and FITC-dextran exclusion assays. The depolymerase exhibited strong activity at nanomolar concentrations, retained function up to 50°C, and was active only against KL51-positive strains, including ST16 and ST231 isolates, but not against strains with other capsule types. Importantly, the depolymerase enabled the lytic activity of the Sugarlandvirus phage GPH82, normally inactive against encapsulated ST16, demonstrating potent phage-depolymerase synergy. These findings highlight the potential of recombinant depolymerases to expand phage host range by unmasking the phage receptors on the surface of the bacteria and therefore enhance the efficacy of phages against encapsulated bacteria. IMPORTANCE: Bacteriophage therapy and phage-derived therapeutics are attracting increasing attention as promising alternatives or adjuvants to antibiotics in the treatment of multidrug-resistant bacterial infections. Among phage-encoded enzymes, depolymerases are of particular interest due to their ability to degrade the bacterial polysaccharide capsule that prevents phage adsorption. Our results highlight the utility of combining recombinant depolymerases with phages to broaden their host range and enhance their activity against encapsulated, drug-resistant pathogens.